

Global Capivasertib Market Growth 2026-2032

<https://marketpublishers.com/r/G65C013967AEEN.html>

Date: July 2026

Pages: 84

Price: US\$ 3,660.00 (Single User License)

ID: G65C013967AEEN

Abstracts

The global Capivasertib market size is predicted to grow from US\$ 712 million in 2025 to US\$ 2751 million in 2032; it is expected to grow at a CAGR of 15.2% from 2026 to 2032.

Capivasertib is an oral, highly selective ATP-competitive AKT kinase inhibitor that potently inhibits the activities of AKT1/2/3 isoforms, blocks the abnormal activation of the PI3K/AKT signaling pathway, and thereby inhibits the proliferation, survival, invasion and metastasis of tumor cells. The drug is mainly developed for patients with solid tumors harboring PIK3CA/AKT1/PTEN mutations. Clinically, it is mostly used in combination with endocrine therapy for HR-positive, HER2-negative advanced breast cancer, and is also under investigation in various tumor types such as prostate cancer and colorectal cancer, providing precise targeted therapeutic options for advanced cancer patients with abnormalities in specific signaling pathways. In 2025, global Capivasertib production reached approximately 1.8 million bottles.

Capivasertib has established a core position in the treatment of HR-positive, HER2-negative advanced breast cancer by virtue of its first-mover advantage as the world's first-in-class AKT inhibitor and a clear biomarker selection strategy. By continuously expanding its pipeline to cover multiple tumor types such as prostate cancer, it has built a broad market space. Its mechanism of action, which precisely targets the PI3K/AKT pathway, aligns perfectly with the mainstream trend of precision and individualized cancer therapy, effectively filling the clinical gap for patients with endocrine resistance. The current market landscape is oligopolistic. As the only approved AKT inhibitor on the market, Capivasertib faces limited direct competition, with only a few similar drugs in late clinical stages. With gradual market access in major global regions, the popularization of companion diagnostics, and the continuous expansion of indications, the drug is rapidly penetrating from second-line breast cancer treatment to more tumor types. It boasts significant long-term commercialization

potential and is expected to become a key product driving the growth of AstraZeneca's oncology business.

LP Information, Inc. (LPI) ' newest research report, the 'Capivasertib Industry Forecast' looks at past sales and reviews total world Capivasertib sales in 2025, providing a comprehensive analysis by region and market sector of projected Capivasertib sales for 2026 through 2032. With Capivasertib sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Capivasertib industry.

This Insight Report provides a comprehensive analysis of the global Capivasertib landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Capivasertib portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Capivasertib market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Capivasertib and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Capivasertib.

This report presents a comprehensive overview, market shares, and growth opportunities of Capivasertib market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

160 mg

200 mg

Segmentation by Combination Therapy:

Capivasertib In Combination With Fulvestrant

Capivasertib In Combination With Letrozole

Segmentation by Sales Channels:

Hospital

Retail

Online

Segmentation by Application:

HR-Positive, HER2-Negative Advanced Breast Cancer

Metastatic Prostate Cancer

Advanced Colorectal Cancer

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

AstraZeneca

Key Questions Addressed in this Report

What is the 10-year outlook for the global Capivasertib market?

What factors are driving Capivasertib market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Capivasertib market opportunities vary by end market size?

How does Capivasertib break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Capivasertib Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Capivasertib by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Capivasertib by Country/Region, 2021, 2025 & 2032
- 2.2 Capivasertib Segment by Type
 - 2.2.1 160 mg
 - 2.2.2 200 mg
 - 2.2.3 Capivasertib Sales by Type
 - 2.2.3.1 Global Capivasertib Sales Market Share by Type (2021-2026)
 - 2.2.3.2 Global Capivasertib Revenue and Market Share by Type (2021-2026)
 - 2.2.3.3 Global Capivasertib Sale Price by Type (2021-2026)
- 2.3 Capivasertib Segment by Combination Therapy
 - 2.3.1 Capivasertib In Combination With Fulvestrant
 - 2.3.2 Capivasertib In Combination With Letrozole
 - 2.3.3 Capivasertib Sales by Combination Therapy
 - 2.3.3.1 Global Capivasertib Sales Market Share by Combination Therapy (2021-2026)
 - 2.3.3.2 Global Capivasertib Revenue and Market Share by Combination Therapy (2021-2026)
 - 2.3.3.3 Global Capivasertib Sale Price by Combination Therapy (2021-2026)
- 2.4 Capivasertib Segment by Sales Channels
 - 2.4.1 Hospital

2.4.2 Retail

2.4.3 Online

2.4.4 Capivasertib Sales by Sales Channels

2.4.4.1 Global Capivasertib Sales Market Share by Sales Channels (2021-2026)

2.4.4.2 Global Capivasertib Revenue and Market Share by Sales Channels
(2021-2026)

2.4.4.3 Global Capivasertib Sale Price by Sales Channels (2021-2026)

2.5 Capivasertib Segment by Application

2.5.1 HR-Positive, HER2-Negative Advanced Breast Cancer

2.5.2 Metastatic Prostate Cancer

2.5.3 Advanced Colorectal Cancer

2.5.4 Others

2.5.5 Capivasertib Sales by Application

2.5.5.1 Global Capivasertib Sale Market Share by Application (2021-2026)

2.5.5.2 Global Capivasertib Revenue and Market Share by Application (2021-2026)

2.5.5.3 Global Capivasertib Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Capivasertib Breakdown Data by Company

3.1.1 Global Capivasertib Annual Sales by Company (2021-2026)

3.1.2 Global Capivasertib Sales Market Share by Company (2021-2026)

3.2 Global Capivasertib Annual Revenue by Company (2021-2026)

3.2.1 Global Capivasertib Revenue by Company (2021-2026)

3.2.2 Global Capivasertib Revenue Market Share by Company (2021-2026)

3.3 Global Capivasertib Sale Price by Company

3.4 Key Manufacturers Capivasertib Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Capivasertib Product Location Distribution

3.4.2 Players Capivasertib Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR CAPIVASERTIB BY GEOGRAPHIC REGION

4.1 World Historic Capivasertib Market Size by Geographic Region (2021-2026)

- 4.1.1 Global Capivasertib Annual Sales by Geographic Region (2021-2026)
- 4.1.2 Global Capivasertib Annual Revenue by Geographic Region (2021-2026)
- 4.2 World Historic Capivasertib Market Size by Country/Region (2021-2026)
 - 4.2.1 Global Capivasertib Annual Sales by Country/Region (2021-2026)
 - 4.2.2 Global Capivasertib Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Capivasertib Sales Growth
- 4.4 APAC Capivasertib Sales Growth
- 4.5 Europe Capivasertib Sales Growth
- 4.6 Middle East & Africa Capivasertib Sales Growth

5 AMERICAS

- 5.1 Americas Capivasertib Sales by Country
 - 5.1.1 Americas Capivasertib Sales by Country (2021-2026)
 - 5.1.2 Americas Capivasertib Revenue by Country (2021-2026)
- 5.2 Americas Capivasertib Sales by Type (2021-2026)
- 5.3 Americas Capivasertib Sales by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Capivasertib Sales by Region
 - 6.1.1 APAC Capivasertib Sales by Region (2021-2026)
 - 6.1.2 APAC Capivasertib Revenue by Region (2021-2026)
- 6.2 APAC Capivasertib Sales by Type (2021-2026)
- 6.3 APAC Capivasertib Sales by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

7.1 Europe Capivasertib by Country

7.1.1 Europe Capivasertib Sales by Country (2021-2026)

7.1.2 Europe Capivasertib Revenue by Country (2021-2026)

7.2 Europe Capivasertib Sales by Type (2021-2026)

7.3 Europe Capivasertib Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Capivasertib by Country

8.1.1 Middle East & Africa Capivasertib Sales by Country (2021-2026)

8.1.2 Middle East & Africa Capivasertib Revenue by Country (2021-2026)

8.2 Middle East & Africa Capivasertib Sales by Type (2021-2026)

8.3 Middle East & Africa Capivasertib Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Capivasertib

10.3 Manufacturing Process Analysis of Capivasertib

10.4 Industry Chain Structure of Capivasertib

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Capivasertib Distributors
- 11.3 Capivasertib Customer

12 WORLD FORECAST REVIEW FOR CAPIVASERTIB BY GEOGRAPHIC REGION

- 12.1 Global Capivasertib Market Size Forecast by Region
 - 12.1.1 Global Capivasertib Forecast by Region (2027-2032)
 - 12.1.2 Global Capivasertib Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global Capivasertib Forecast by Type (2027-2032)
- 12.7 Global Capivasertib Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

- 13.1 AstraZeneca
 - 13.1.1 AstraZeneca Company Information
 - 13.1.2 AstraZeneca Capivasertib Product Portfolios and Specifications
 - 13.1.3 AstraZeneca Capivasertib Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.1.4 AstraZeneca Main Business Overview
 - 13.1.5 AstraZeneca Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Capivasertib Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Table 2. Capivasertib Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of 160 mg
- Table 4. Major Players of 200 mg
- Table 5. Global Capivasertib Sales by Type (2021-2026) & (Units)
- Table 6. Global Capivasertib Sales Market Share by Type (2021-2026)
- Table 7. Global Capivasertib Revenue by Type (2021-2026) & (\$ million)
- Table 8. Global Capivasertib Revenue Market Share by Type (2021-2026)
- Table 9. Global Capivasertib Sale Price by Type (2021-2026) & (US\$/Unit)
- Table 10. Major Players of Capivasertib In Combination With Fulvestrant
- Table 11. Major Players of Capivasertib In Combination With Letrozole
- Table 12. Global Capivasertib Sales by Combination Therapy (2021-2026) & (Units)
- Table 13. Global Capivasertib Sales Market Share by Combination Therapy (2021-2026)
- Table 14. Global Capivasertib Revenue by Combination Therapy (2021-2026) & (\$ million)
- Table 15. Global Capivasertib Revenue Market Share by Combination Therapy (2021-2026)
- Table 16. Global Capivasertib Sale Price by Combination Therapy (2021-2026) & (US\$/Unit)
- Table 17. Major Players of Hospital
- Table 18. Major Players of Retail
- Table 19. Major Players of Online
- Table 20. Global Capivasertib Sales by Sales Channels (2021-2026) & (Units)
- Table 21. Global Capivasertib Sales Market Share by Sales Channels (2021-2026)
- Table 22. Global Capivasertib Revenue by Sales Channels (2021-2026) & (\$ million)
- Table 23. Global Capivasertib Revenue Market Share by Sales Channels (2021-2026)
- Table 24. Global Capivasertib Sale Price by Sales Channels (2021-2026) & (US\$/Unit)
- Table 25. Global Capivasertib Sale by Application (2021-2026) & (Units)
- Table 26. Global Capivasertib Sale Market Share by Application (2021-2026)
- Table 27. Global Capivasertib Revenue by Application (2021-2026) & (\$ million)
- Table 28. Global Capivasertib Revenue Market Share by Application (2021-2026)
- Table 29. Global Capivasertib Sale Price by Application (2021-2026) & (US\$/Unit)

Table 30. Global Capivasertib Sales by Company (2021-2026) & (Units)
Table 31. Global Capivasertib Sales Market Share by Company (2021-2026)
Table 32. Global Capivasertib Revenue by Company (2021-2026) & (\$ millions)
Table 33. Global Capivasertib Revenue Market Share by Company (2021-2026)
Table 34. Global Capivasertib Sale Price by Company (2021-2026) & (US\$/Unit)
Table 35. Key Manufacturers Capivasertib Producing Area Distribution and Sales Area
Table 36. Players Capivasertib Products Offered
Table 37. Capivasertib Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Capivasertib Sales by Geographic Region (2021-2026) & (Units)
Table 41. Global Capivasertib Sales Market Share Geographic Region (2021-2026)
Table 42. Global Capivasertib Revenue by Geographic Region (2021-2026) & (\$ millions)
Table 43. Global Capivasertib Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Capivasertib Sales by Country/Region (2021-2026) & (Units)
Table 45. Global Capivasertib Sales Market Share by Country/Region (2021-2026)
Table 46. Global Capivasertib Revenue by Country/Region (2021-2026) & (\$ millions)
Table 47. Global Capivasertib Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Capivasertib Sales by Country (2021-2026) & (Units)
Table 49. Americas Capivasertib Sales Market Share by Country (2021-2026)
Table 50. Americas Capivasertib Revenue by Country (2021-2026) & (\$ millions)
Table 51. Americas Capivasertib Sales by Type (2021-2026) & (Units)
Table 52. Americas Capivasertib Sales by Application (2021-2026) & (Units)
Table 53. APAC Capivasertib Sales by Region (2021-2026) & (Units)
Table 54. APAC Capivasertib Sales Market Share by Region (2021-2026)
Table 55. APAC Capivasertib Revenue by Region (2021-2026) & (\$ millions)
Table 56. APAC Capivasertib Sales by Type (2021-2026) & (Units)
Table 57. APAC Capivasertib Sales by Application (2021-2026) & (Units)
Table 58. Europe Capivasertib Sales by Country (2021-2026) & (Units)
Table 59. Europe Capivasertib Revenue by Country (2021-2026) & (\$ millions)
Table 60. Europe Capivasertib Sales by Type (2021-2026) & (Units)
Table 61. Europe Capivasertib Sales by Application (2021-2026) & (Units)
Table 62. Middle East & Africa Capivasertib Sales by Country (2021-2026) & (Units)
Table 63. Middle East & Africa Capivasertib Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Capivasertib Sales by Type (2021-2026) & (Units)
Table 65. Middle East & Africa Capivasertib Sales by Application (2021-2026) & (Units)

Table 66. Key Market Drivers & Growth Opportunities of Capivasertib
Table 67. Key Market Challenges & Risks of Capivasertib
Table 68. Key Industry Trends of Capivasertib
Table 69. Capivasertib Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Capivasertib Distributors List
Table 72. Capivasertib Customer List
Table 73. Global Capivasertib Sales Forecast by Region (2027-2032) & (Units)
Table 74. Global Capivasertib Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 75. Americas Capivasertib Sales Forecast by Country (2027-2032) & (Units)
Table 76. Americas Capivasertib Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 77. APAC Capivasertib Sales Forecast by Region (2027-2032) & (Units)
Table 78. APAC Capivasertib Annual Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 79. Europe Capivasertib Sales Forecast by Country (2027-2032) & (Units)
Table 80. Europe Capivasertib Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 81. Middle East & Africa Capivasertib Sales Forecast by Country (2027-2032) & (Units)
Table 82. Middle East & Africa Capivasertib Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 83. Global Capivasertib Sales Forecast by Type (2027-2032) & (Units)
Table 84. Global Capivasertib Revenue Forecast by Type (2027-2032) & (\$ millions)
Table 85. Global Capivasertib Sales Forecast by Application (2027-2032) & (Units)
Table 86. Global Capivasertib Revenue Forecast by Application (2027-2032) & (\$ millions)
Table 87. AstraZeneca Basic Information, Capivasertib Manufacturing Base, Sales Area and Its Competitors
Table 88. AstraZeneca Capivasertib Product Portfolios and Specifications
Table 89. AstraZeneca Capivasertib Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
Table 90. AstraZeneca Main Business
Table 91. AstraZeneca Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Capivasertib
- Figure 2. Capivasertib Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Capivasertib Sales Growth Rate 2021-2032 (Units)
- Figure 7. Global Capivasertib Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Capivasertib Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Capivasertib Sales Market Share by Country/Region (2025)
- Figure 10. Capivasertib Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of 160 mg
- Figure 12. Product Picture of 200 mg
- Figure 13. Global Capivasertib Sales Market Share by Type in 2026
- Figure 14. Global Capivasertib Revenue Market Share by Type (2021-2026)
- Figure 15. Product Picture of Capivasertib In Combination With Fulvestrant
- Figure 16. Product Picture of Capivasertib In Combination With Letrozole
- Figure 17. Global Capivasertib Sales Market Share by Combination Therapy in 2026
- Figure 18. Global Capivasertib Revenue Market Share by Combination Therapy (2021-2026)
- Figure 19. Product Picture of Hospital
- Figure 20. Product Picture of Retail
- Figure 21. Product Picture of Online
- Figure 22. Global Capivasertib Sales Market Share by Sales Channels in 2026
- Figure 23. Global Capivasertib Revenue Market Share by Sales Channels (2021-2026)
- Figure 24. Capivasertib Consumed in HR-Positive, HER2-Negative Advanced Breast Cancer
- Figure 25. Global Capivasertib Market: HR-Positive, HER2-Negative Advanced Breast Cancer (2021-2026) & (Units)
- Figure 26. Capivasertib Consumed in Metastatic Prostate Cancer
- Figure 27. Global Capivasertib Market: Metastatic Prostate Cancer (2021-2026) & (Units)
- Figure 28. Capivasertib Consumed in Advanced Colorectal Cancer
- Figure 29. Global Capivasertib Market: Advanced Colorectal Cancer (2021-2026) & (Units)
- Figure 30. Capivasertib Consumed in Others

- Figure 31. Global Capivasertib Market: Others (2021-2026) & (Units)
- Figure 32. Global Capivasertib Sale Market Share by Application (2025)
- Figure 33. Global Capivasertib Revenue Market Share by Application in 2025
- Figure 34. Capivasertib Sales by Company in 2025 (Units)
- Figure 35. Global Capivasertib Sales Market Share by Company in 2025
- Figure 36. Capivasertib Revenue by Company in 2025 (\$ millions)
- Figure 37. Global Capivasertib Revenue Market Share by Company in 2025
- Figure 38. Global Capivasertib Sales Market Share by Geographic Region (2021-2026)
- Figure 39. Global Capivasertib Revenue Market Share by Geographic Region in 2025
- Figure 40. Americas Capivasertib Sales 2021-2026 (Units)
- Figure 41. Americas Capivasertib Revenue 2021-2026 (\$ millions)
- Figure 42. APAC Capivasertib Sales 2021-2026 (Units)
- Figure 43. APAC Capivasertib Revenue 2021-2026 (\$ millions)
- Figure 44. Europe Capivasertib Sales 2021-2026 (Units)
- Figure 45. Europe Capivasertib Revenue 2021-2026 (\$ millions)
- Figure 46. Middle East & Africa Capivasertib Sales 2021-2026 (Units)
- Figure 47. Middle East & Africa Capivasertib Revenue 2021-2026 (\$ millions)
- Figure 48. Americas Capivasertib Sales Market Share by Country in 2025
- Figure 49. Americas Capivasertib Revenue Market Share by Country (2021-2026)
- Figure 50. Americas Capivasertib Sales Market Share by Type (2021-2026)
- Figure 51. Americas Capivasertib Sales Market Share by Application (2021-2026)
- Figure 52. United States Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 53. Canada Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 54. Mexico Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 55. Brazil Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 56. APAC Capivasertib Sales Market Share by Region in 2025
- Figure 57. APAC Capivasertib Revenue Market Share by Region (2021-2026)
- Figure 58. APAC Capivasertib Sales Market Share by Type (2021-2026)
- Figure 59. APAC Capivasertib Sales Market Share by Application (2021-2026)
- Figure 60. China Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 61. Japan Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 62. South Korea Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 63. Southeast Asia Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 64. India Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 65. Australia Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 66. China Taiwan Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 67. Europe Capivasertib Sales Market Share by Country in 2025
- Figure 68. Europe Capivasertib Revenue Market Share by Country (2021-2026)
- Figure 69. Europe Capivasertib Sales Market Share by Type (2021-2026)

- Figure 70. Europe Capivasertib Sales Market Share by Application (2021-2026)
- Figure 71. Germany Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 72. France Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 73. UK Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 74. Italy Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 75. Russia Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 76. Middle East & Africa Capivasertib Sales Market Share by Country (2021-2026)
- Figure 77. Middle East & Africa Capivasertib Sales Market Share by Type (2021-2026)
- Figure 78. Middle East & Africa Capivasertib Sales Market Share by Application (2021-2026)
- Figure 79. Egypt Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 80. South Africa Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 81. Israel Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 82. Turkey Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 83. GCC Countries Capivasertib Revenue Growth 2021-2026 (\$ millions)
- Figure 84. Manufacturing Cost Structure Analysis of Capivasertib in 2026
- Figure 85. Manufacturing Process Analysis of Capivasertib
- Figure 86. Industry Chain Structure of Capivasertib
- Figure 87. Channels of Distribution
- Figure 88. Global Capivasertib Sales Market Forecast by Region (2027-2032)
- Figure 89. Global Capivasertib Revenue Market Share Forecast by Region (2027-2032)
- Figure 90. Global Capivasertib Sales Market Share Forecast by Type (2027-2032)
- Figure 91. Global Capivasertib Revenue Market Share Forecast by Type (2027-2032)
- Figure 92. Global Capivasertib Sales Market Share Forecast by Application (2027-2032)
- Figure 93. Global Capivasertib Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Capivasertib Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G65C013967AEEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G65C013967AEEN.html>